Identifying and validating vaccine candidates

Vaccine development –  It’s in our blood

With its rapid, high throughput identification and characterization of vaccines, BioCopy can achieve a major time advantage. Time that can be worth millions: millions of human lives in the event of a pandemic – millions in sales and a unique market position due to a head start in market approval.

Pascal Brenneisen

Member of the Board of Directors of BioCopy AG